Patent ID: 11872288
Assignee: PHILOGEN S.P.A.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A

Claim 10:
11. A method of treating a glioma in a patient, comprising administering a TNFα immunoconjugate in combination with chemotherapy to the patient, wherein the TNFα immunoconjugate comprises TNFα linked to an antibody molecule comprising L19 complementarity determining regions (CDRs), wherein the L19 CDRs are:, SEQ ID NO: 1

VH CDR1
SFSMS

 

SEQ ID NO: 2

VH CDR 2
SISGSSGTTYYADSVKG

 

SEQ ID NO: 3

VH CDR 3
PFPYFDY

 

SEQ ID NO: 4

VL CDR 1
RASQSVSSSFLA

 

SEQ ID NO: 5

VL CDR 2
YASSRAT, and

 

SEQ ID NO: 6

VL CDR 3
QQTGRIPPT;

wherein the chemotherapy is lomustine;
wherein the antibody molecule comprises the L19 VH domain SEQ ID NO: 7 and the L19 VL domain SEQ ID NO: 9;
wherein the TNFα immunoconjugate comprises TNFα linked to L19 (scFv) as set forth in SEQ ID NO: 10 and
the TNFα immunoconjugate has an amino acid sequence of SEQ ID NO: 13.